Growing Established Pharma Products: Three Strategic Imperatives
The global pharmaceutical market has seen a remarkable resurgence of innovation in the past few years, and in this exciting era it's easy to lose sight of the launches of yesteryear that are the established products of today. But for many companies, disease areas and countries, these older brands are the bedrock of business and treatment.
You may also be interested in...
QuintilesIMS' research demonstrates that the preference for one set of digital channels varies widely by HCP specialty and country. A single physician’s channel preference can vary by the disease area for which they receive communication. How can companies, faced with such complexity, ever hope to master customer preference?
Pharma is one of the last industries to hold on to the use of sales representatives to sell its goods. It's time to harness digital technologies that enable multiple ways to approach clients on their own terms.
Compared with their top 20 European peers and with similarly sized companies in the US, many mid-sized European pharmas are struggling. IMS Health analyzes the predicament these companies find themselves in and outlines what they need to do to avoid being caught in an evolutionary backwater.